This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Editas, Allergan Start Dosing in Early-Stage Eye Disease Study
by Zacks Equity Research
Editas (EDIT) and Allergan are co-developing a CRISPR-based candidate, AGN-151587, for treating Leber congenital amaurosis 10 (LCA10), an inherited form of blindness.
Infinity (INFI) Q4 Loss Wider Than Expected, IPI-549 in Focus
by Zacks Equity Research
Infinity (INFI) posts a wider-than-expected loss for the fourth quarter of 2019.
The Extreme Risks of Trading Your Own Retirement Assets - March 04, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Sanofi's Sarclisa Gets FDA Nod for Third-Line Multiple Myeloma
by Zacks Equity Research
The FDA approves Sanofi's (SNY) Sarclisa (isatuximab) combo for the treatment of adult patients with relapsed refractory multiple myeloma in the third-line setting.
MorphoSys BLA for Cancer Drug Gets Priority Review from FDA
by Zacks Equity Research
MorphoSys (MOR) BLA for blood cancer drug gets Priority Review from the FDA.
Bristol-Myers Squibb (BMY) Stock Moves -0.87%: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed at $59.06 in the latest trading session, marking a -0.87% move from the prior day.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks - February 28, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Nektar (NKTR) Q4 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Nektar (NKTR) reports encouraging fourth-quarter results. The company continues to progress with its pipeline candidates.
Editas (EDIT) Q4 Earnings & Sales Fall Shy of Estimates
by Zacks Equity Research
Editas (EDIT) misses on earnings and revenues in fourth-quarter 2019.
Easy Investing Secrets to an Early Retirement - February 27, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FLQL
Clovis (CLVS) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Clovis (CLVS) reports mixed fourth-quarter 2019 results. The company's sole marketed drug, Rubraca, drives revenues. Shares down.
Signs That Your Trading Will Ruin Your Retirement - February 25, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Bristol-Myers Squibb (BMY) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Roche's Tecentriq sBLA for Lung Cancer Gets Priority Review
by Kinjel Shah
Roche (RHHBY) gets FDA's priority review status for a sBLA for Tecentriq monotherapy in first-line treatment of certain people with advanced non-small cell lung cancer.
What's in Store for Jounce (JNCE) This Earnings Season?
by Zacks Equity Research
Investors will look forward to pipeline updates when clinical-stage immunotherapy company, Jounce (JNCE), reports Q4 results.
bluebird (BLUE) Q4 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
bluebird (BLUE) reports a wider-than-expected loss and in-line revenues for the fourth quarter of 2019.
Is a Beat in the Cards for Clovis' (CLVS) Earnings in Q4?
by Zacks Equity Research
Clovis' (CLVS) sole marketed drug, Rubraca, is likely to have driven revenues in the fourth quarter.
Easy Investing Secrets to an Early Retirement - February 19, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Signs That Your Trading Will Ruin Your Retirement - February 17, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Agios' (AGIO) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Agios (AGIO) rides high on earnings and revenue beat in the fourth quarter of 2019.
Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails
by Kinjel Shah
AbbVie (ABBV) and Allergan (AGN) announce Q4 results.
Bristol-Myers' (BMY) CAR T Cell Therapy Gets Priority Review
by Zacks Equity Research
Bristol-Myers' (BMY) BLA for lisocabtagene maraleucel gets Priority Review from the FDA.
Prothena (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Prothena (PRTA) reports a narrower-than-expected Q4 loss, while revenues surpass estimates.